You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for New Drug Application (NDA): 218158


✉ Email this page to a colleague

« Back to Dashboard


NDA 218158 describes CLOBETASOL PROPIONATE, which is a drug marketed by Alembic, Glenmark Pharms Ltd, Novast Labs, Padagis Israel, Taro, Amneal, Aurobindo Pharma Usa, Chartwell Rx, Cosette, Encube, Fougera Pharms Inc, Glenmark Speclt, Lupin Ltd, Pai Holdings Pharm, Rising, Teva Pharms Usa, Torrent, Xiromed, Zydus Pharms, Fougera Pharms, Padagis Us, Actavis Mid Atlantic, Epic Pharma Llc, Zydus Lifesciences, Macleods Pharms Ltd, Novel Labs Inc, Hikma, Prinston Inc, Quagen, Saptalis Pharms, Wockhardt Bio Ag, Apotex, Sciegen Pharms Inc, Eyenovia, and Ani Pharms, and is included in eighty-one NDAs. It is available from thirty-seven suppliers. There are two patents protecting this drug. Additional details are available on the CLOBETASOL PROPIONATE profile page.

The generic ingredient in CLOBETASOL PROPIONATE is clobetasol propionate. There are fourteen drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the clobetasol propionate profile page.
Summary for 218158
Tradename:CLOBETASOL PROPIONATE
Applicant:Eyenovia
Ingredient:clobetasol propionate
Patents:2
Pharmacology for NDA: 218158
Medical Subject Heading (MeSH) Categories for 218158
Suppliers and Packaging for NDA: 218158
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CLOBETASOL PROPIONATE clobetasol propionate SUSPENSION/DROPS;OPHTHALMIC 218158 NDA Eyenovia, Inc. 81046-0319 81046-0319-1 1 BOTTLE, DROPPER in 1 CARTON (81046-0319-1) / 3.5 mL in 1 BOTTLE, DROPPER
CLOBETASOL PROPIONATE clobetasol propionate SUSPENSION/DROPS;OPHTHALMIC 218158 NDA Bora Pharmaceuticals Ophthalmic Inc. Taoyuan plant 81772-007 81772-007-01 1 BOTTLE, DROPPER in 1 CARTON (81772-007-01) / 3.5 mL in 1 BOTTLE, DROPPER

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SUSPENSION/DROPS;OPHTHALMICStrength0.05%
Approval Date:Mar 4, 2024TE:RLD:Yes
Regulatory Exclusivity Expiration:Mar 4, 2027
Regulatory Exclusivity Use:NEW PRODUCT
Patent:⤷  Sign UpPatent Expiration:May 9, 2036Product Flag?YSubstance Flag?Delist Request?
Patent:⤷  Sign UpPatent Expiration:May 9, 2036Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF INFLAMMATION

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.